Sort
15,273 grants matching “antimicrobial resistance”
IND-enabling studies of the potent LpxC inhibitor LPC-233 as a novel antibiotic against Gram-negative pathogens
$797,403Clayton Duncan · Valanbio Therapeutics, Inc. · R44 · FY2020 · AI
Bacillus subtilis stress responses
$797,005John D. Helmann · Cornell University · R35 · FY2023 · GM
Antimicrobial, Angiogenic Skin Substitutes for Diabetic*
$796,845John M Centanni · Stratatech Corporation · R44 · FY2007 · DK
Innate Immune Clearance of Host-Adapted Pulmonary Pathogens
$796,640Alice S Prince · Columbia University Health Sciences · R35 · FY2017 · HL
Novel medical device for treatment of fungal nail infection
$796,589Jeffrey N Roe · Devicefarm, Inc. · R44 · FY2017 · GM
Single-cell based diagnostic platform with single-molecular transcriptional response profiling for rapid phenotypic antimicrobial susceptibility testing of gonorrhea
$796,454Tza-Huei Jeff Wang · Johns Hopkins University · R01 · FY2024 · AI
Neisseria gonorrhoeae exploits host interferon epsilon to establish infection in the female urogenital tract
$796,136Douglas T. Golenbock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2022 · AI
Neisseria gonorrhoeae exploits host interferon epsilon to establish infection in the female urogenital tract
$796,136Douglas T. Golenbock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2023 · AI
Bacillus subtilis stress responses
$795,999John D. Helmann · Cornell University · R35 · FY2025 · GM
Early life antibiotics, gut microbiome development, and risk of childhood obesity
$795,962Jeffrey Stephen Gerber · Children'S Hosp Of Philadelphia · R01 · FY2016 · AI
Novel mycobacterial translocase I inhibitors - a new class of anti-TB drugs
$795,701Venkata M Reddy · Sequella, Inc. · R44 · FY2009 · AI
Defining functional humoral correlates of immunity to guide vaccine design
$795,292Facundo Damian Batista · Massachusetts General Hospital · R01 · FY2023 · AI
Biochemistry of Energy-Dependent (Intracellular) Protein Degradation
$795,262Michael Maurizi · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Effects of early life Triclosan exposure through lactation on the gut-liver axis and its implications in the development of steatotic liver disease in adults
$794,841Robert H Tukey · University Of California, San Diego · R01 · FY2025 · ES
Targeting the Urgent Need for New Antibiotics against Gram-negative âSuperbugsâ
$794,600Jian Li · Monash University · R01 · FY2019 · AI
Measuring and Predicting Appropriate Antibiotic Use to Combat Resistant Bacteria
$794,489Jonathan H. Chen · Stanford University · R01 · FY2023 · AI
IND-enabling studies of the potent LpxC inhibitor LPC-233 as a novel antibiotic against Gram-negative pathogens
$794,342Clayton Duncan · Valanbio Therapeutics, Inc. · R44 · FY2021 · AI
Development of Antibiotic Adjuvants for Gram-Negative Bacteria
$794,128Christian C Melander · University Of Notre Dame · R01 · FY2018 · AI
Novel Biamyxins targeting multidrug resistant Gram-negative bacterial infections
$793,943Yanan Zhao · State University Of New York At Buffalo · R01 · FY2025 · AI
Novel mycobacterial translocase I inhibitors - a new class of anti-TB drugs
$793,901Venkata M Reddy · Sequella, Inc. · R44 · FY2008 · AI
Preclinical modeling to study Tuberculous Meningitis
$793,509Sanjay Jain · Johns Hopkins University · R01 · FY2022 · AI
Advancing pharmacy-based delivery of primary STI and HIV prevention for cisgender women
$793,462Jillian Pintye · University Of Washington · R01 · FY2025 · HD
Novel, Non-Toxic Ocular Antiseptic For Intravitreal Injection Therapy
$793,154Stephen J Smith · Irenix Medical, Inc. · R44 · FY2022 · EY
Mechanisms of Chromosome Maintenance in Bacteria
$793,068Dhruba K Chattoraj · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
RNA: New Antimicrobial Strategies
$792,887Adrian Ferre-D'amare · National Heart, Lung, And Blood Institute · ZIA · FY2021 · HL